A surge in demand for GLP-1 receptor agonist drugs such as Ozempic has led to thousands of lawsuits alleging serious side effects, including gastrointestinal injuries and vision loss. The drugs, which were initially approved for type 2 diabetes, have become popular for weight loss, with over 4,000 lawsuits filed against manufacturers Novo Nordisk and Eli Lilly.

Side Effects and Lawsuits

The lawsuits claim that the manufacturers failed to adequately warn about the risks of the drugs, which include gastrointestinal injuries such as gastroparesis, intestinal blockages, and gallbladder problems, as well as vision loss and thyroid cancer. The FDA has received reports of over 4,400 adverse events related to the drugs, including 110 cases of vision loss.

Some reports reference potential damages in the billions, though no global settlements have been reached. The manufacturers maintain that the drugs are safe when used as prescribed and deny liability.

Regulatory Response

The FDA has approved the drugs for type 2 diabetes and obesity, but the agency has also issued warnings about the potential risks. The FDA has received reports of serious side effects, including pancreatitis, NAION (non-arteritic anterior ischemic optic neuropathy), and thyroid cancer.

The phenomenon known as “Ozempic face,” characterized by sagging skin, hollowed cheeks, sunken eyes, and a gaunt appearance, has also been reported. Studies have shown that the drugs can lead to significant weight loss, but also to facial fat and muscle loss.

Original reporting: The Dallas Express — read the source article.